1.Iranian Registry of Crohn's and Colitis: study profile of first nation-wide inflammatory bowel disease registry in Middle East
Masoud M MALEKZADEH ; Alireza SIMA ; Sudabeh ALATAB ; Anahita SADEGHI ; Nasser Ebrahimi DARYANI ; Payman ADIBI ; Iradj MALEKI ; Hassan VOSSOUGHINIA ; Hafez FAKHERI ; Abbas YAZDANBOD ; Seyed Alireza TAGHAVI ; Rahim AGHAZADEH ; Mohammad Hassan SOMI ; Kazem ZENDEDEL ; Homayoon VAHEDI ; Reza MALEKZADEH
Intestinal Research 2019;17(3):330-339
BACKGROUND/AIMS: A recent study revealed increasing incidence and prevalence of inflammatory bowel disease (IBD) in Iran. The Iranian Registry of Crohn's and Colitis (IRCC) was designed recently to answer the needs. We reported the design, methods of data collection, and aims of IRCC in this paper. METHODS: IRCC is a multicenter prospective registry, which is established with collaboration of more than 100 gastroenterologists from different provinces of Iran. Minimum data set for IRCC was defined according to an international consensus on standard set of outcomes for IBD. A pilot feasibility study was performed on 553 IBD patients with a web-based questionnaire. The reliability of questionnaire evaluated by Cronbach's α. RESULTS: All sections of questionnaire had Cronbach's α of more than 0.6. In pilot study, 312 of participants (56.4%) were male and mean age was 38 years (standard deviation=12.8) and 378 patients (68.35%) had ulcerative colitis, 303 subjects (54,7%) had college education and 358 patients (64.74%) were of Fars ethnicity. We found that 68 (12.3%), 44 (7.9%), and 13 (2.3%) of participants were smokers, hookah and opium users, respectively. History of appendectomy was reported in 58 of patients (10.48%). The most common medication was 5-aminosalicylate (94.39%). CONCLUSIONS: To the best of our knowledge, IRCC is the first national IBD registry in the Middle East and could become a reliable infrastructure for national and international research on IBD. IRCC will improve the quality of care of IBD patients and provide national information for policy makers to better plan for controlling IBD in Iran.
Administrative Personnel
;
Appendectomy
;
Colitis
;
Colitis, Ulcerative
;
Consensus
;
Cooperative Behavior
;
Data Collection
;
Dataset
;
Education
;
Feasibility Studies
;
Humans
;
Incidence
;
Inflammatory Bowel Diseases
;
Iran
;
Male
;
Mesalamine
;
Middle East
;
Opium
;
Pilot Projects
;
Prevalence
;
Prospective Studies
2.A randomized, double blinded, placebo-controlled clinical trial of silymarin in ulcerative colitis.
Mansoor RASTEGARPANAH ; Reza MALEKZADEH ; Homayoun VAHEDI ; Maryam MOHAMMADI ; Elham ELAHI ; Meghedi CHAHARMAHALI ; Tahereh SAFARNAVADEH ; Mohammad ABDOLLAHI
Chinese journal of integrative medicine 2015;21(12):902-906
OBJECTIVETo evaluate the clinical efficacy of silymarin in ulcerative colitis (UC) patients.
METHODSA randomized double blinded placebo-controlled clinical trial was conducted in 80 UC patients whose disease had been documented and were in remission state between September 2009 and October 2010. Patients were assigned to silymarin group (42 cases) and placebo group (38 cases) using a random number table. Either silymarin (140 mg) or placebo (lactose mono-hydrate, corn starch magnesium stearate) tablets were given once daily for 6 months along with their standard therapy. The efficacies were assessed by disease activity index (DAI), frequency difference of the disease flare-up, and paraclinical data.
RESULTSTen patients (4 in the silymarin group due to nausea and 6 in the placebo group due to disease flare-up and abdominal pain) discontinued the study. An improvement in hemoglobin level (11.8±1.6 g/dL vs. 13.4±1.2 g/dL,P<0.05) and erythrocyte sedimentation rate (23.7±11.5 mm/h vs.10.8±3.2 mm/h,P<0.05) was observed in the silymarin group but not in the placebo group. DAI significantly decreased in the silymarin group and reached from 11.3±3.5 to 10.7±2.8 (P<0.05). Thirty-five out of 38 patients in the silymarin group were in complete remission with no flare-up after 6 months as compared to 21 out of 32 patients in the placebo group (P=0.5000).
CONCLUSIONSilymarin as a natural supplement may be used in UC patients to maintain remission.
Adolescent ; Adult ; Aged ; Colitis, Ulcerative ; drug therapy ; Double-Blind Method ; Female ; Humans ; Male ; Middle Aged ; Pilot Projects ; Silymarin ; therapeutic use